Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT
ASCO20 Virtual Scientific ProgramChristopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).
Related Videos
Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2<...
Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program
As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks w...
Reshma Jagsi, MD, DPhil, and Narjust Duma, MD, on Diversity in Oncology: A Discussion of Evidence-Based Transformation
Reshma Jagsi, MD, DPhil, of the University of Michigan, and Narjust Duma, MD, of the University of Wisconsin Carbone Cancer Center, discuss the state of dive...
Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage IB–IIIA EGFR Mutation–Positive Disease
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete t...
Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at...
